Register for our free email digests:
Latest From Food & Drug Administration
Which immuno-oncology candidates are poised to begin their first-in-human clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Citeline's Rachel L. Meighan-Mantha has the data.
Mobile technology and wearables have been hailed by many as the golden future for operational efficiency and patient retention in clinical studies. Digital engagement expert Tim Davis discusses the pitfalls of selecting a one-size-fits-all strategy and waiting for trial processes and regulators to catch up.
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Pacific Rim
- Parent & Subsidiaries
- REGiMMUNE Corp.
- Senior Management
Haru Morita, Pres. & CEO
Reiko Namikawa, MD, PhD, SVP, Dev. & Strategy
Teikichi Aoyagi, PhD, SVP, Chief Dev. Officer
- Contact Info
Phone: (81) 3 3456 0820
Tokyo Industry Trade Ctr. 607
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.